Natalizumab in the pediatric MS population: Results of the Italian registry

Angelo Ghezzi, Lucia Moiola, Carlo Pozzilli, Vincenzo Brescia-Morra, Paolo Gallo, Luigi Maria Edoardo Grimaldi, Massimo Filippi, Giancarlo Comi G.

Research output: Contribution to journalArticlepeer-review


Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on this topic. Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before 18 years of age. Results: 101 patients were included (69 females), mean age of MS onset 12.9±2.7 years, mean age at NA initiation 14.7±2.4 years. Mean treatment duration was 34.2±18.3 months. During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3±1.0 in the year prior to NA and decreased to 0.1±0.3 (p

Original languageEnglish
Article number174
JournalBMC Neurology
Issue number1
Publication statusPublished - Sep 25 2015

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Natalizumab in the pediatric MS population: Results of the Italian registry'. Together they form a unique fingerprint.

Cite this